Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: Implications for the branched-chain amino acid oxidation pathway

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1155-1160

  Luís, Paula B M ^a,b   Ruiter, Jos P N ^b   IJlst, Lodewijk ^b   De Almeida, Isabel Tavares ^a   Duran, Marinus ^b   Mohsen, Al Walid ^c   Vockley, Jerry ^c   Wanders, Ronald J A ^b   Silva, Margarida F B ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; COENZYME A; ISOBUTYRYL COENZYME A DEHYDROGENASE; ISOLEUCINE; ISOVALERYL COENZYME A DEHYDROGENASE; LEUCINE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VALINE; VALPROIC ACID; VALPROLYL COENZYME A; VALPROLYL DEPHOSPHO COENZYME A;

AMINO ACID METABOLISM; ARTICLE; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEHYDROGENATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE COMPLEX; FATTY ACID OXIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; OXIDATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACIDS, BRANCHED-CHAIN; BUTYRYL-COA DEHYDROGENASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ISOVALERYL-COA DEHYDROGENASE; OXIDATION-REDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; VALPROIC ACID;

EID: 79959447995     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037606     Document Type: Article

References (30)

1. Anderson GD, Acheampong AA, and Levy RH (1994) Interaction between valproate and branched-chain amino acid metabolism. Neurology 44:742-744. (Pubitemid 24130009)
2. Battaile KP, Nguyen TV, Vockley J, and Kim JJ (2004) Structures of isobutyryl-CoA dehydrogenase and enzyme-product complex: comparison with isovaleryl- and short-chain acyl-CoA dehydrogenases. J Biol Chem 279:16526-16534. (Pubitemid 38509352)
3. Bialer M and Yagen B (2007) Valproic acid: second generation. Neurotherapeutics 4:130-137. (Pubitemid 46107326)
4. Bissell DM, Gores GJ, Laskin DL, and Hoofnagle JH (2001) Drug-induced liver injury: mechanisms and test systems. Hepatology 33:1009-1013. (Pubitemid 32246655)
5. Björnsson E (2008) Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 118:281-290.
6. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55:170-171.
7. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz- Hernandez E, and Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206-222.
8. Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD, Antonias JI, and Schimschock JC (1979) Reye-like syndrome associated with valproic acid therapy. J Pediatr 95:142-144. (Pubitemid 9183702)
9. Gibson KM, Burlingame TG, Hogema B, Jakobs C, Schutgens RB, Millington D, Roe CR, Roe DS, Sweetman L, Steiner RD, et al. (2000) 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of L-isoleucine metabolism. Pediatr Res 47:830-833. (Pubitemid 30365447)
10. He M, Burghardt TP, and Vockley J (2003) A novel approach to the characterization of substrate specificity in short/branched chain Acyl-CoA dehydrogenase. J Biol Chem 278:37974-37986. (Pubitemid 37175328)
11. Ito M, Ikeda Y, Arnez JG, Finocchiaro G, and Tanaka K (1990) The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta 1034:213-218. (Pubitemid 20157830)
12. Korman SH (2006) Inborn errors of isoleucine degradation: a review. Mol Genet Metab 89:289-299.
13. Li J, Norwood DL, Mao LF, and Schulz H (1991) Mitochondrial metabolism of valproic acid. Biochemistry 30:388-394.
14. Masuccio F, Verrotti A, Chiavaroli V, Giorgis T, Giannini C, Chiarelli F, and Mohn A (2010) Weight gain and insulin resistance in children treated with valproate: the influence of time. J Child Neurol 25:941-947.
15. Mohsen AW and Vockley J (1995) High-level expression of an altered cDNA encoding human isovaleryl-CoA dehydrogenase in Escherichia coli. Gene 160:263-267.
16. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, and Svetkey LP. (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9:311-326.
17. Nguyen TV, Andresen BS, Corydon TJ, Ghisla S, Abd-El Razik N, Mohsen AW, Cederbaum SD, Roe DS, Roe CR, Lench NJ, et al. (2002) Identification of isobutyryl-CoA dehydrogenase and its deficiency in humans. Mol Genet Metab 77:68-79. (Pubitemid 35178517)
18. Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16:695-714.
19. Peterson GM and Naunton M (2005) Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 30:417-421. (Pubitemid 41603013)
20. Rasmussen JT, Börchers T, and Knudsen J (1990) Comparison of the binding affinities of acyl-CoA-binding protein and fatty-acid-binding protein for long-chain acyl-CoA esters. Biochem J 265:849-855. (Pubitemid 20053891)
21. Silva MF, Ruiter JP, Ijlst L, Jakobs C, Duran M, de Almeida IT, and Wanders RJ (2001a) Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem Biol Interact 137:203-212. (Pubitemid 32879336)
22. Silva MF, Ruiter JP, Ijlst L, Allers P, ten Brink HJ, Jakobs C, Duran M, Tavares de Almeida I, and Wanders RJ (2001b) Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites. Anal Biochem 290:60-67.
23. Silva MF, Ruiter JP, Overmars H, Bootsma AH, van Gennip AH, Jakobs C, Duran M, Tavares de Almeida I, and Wanders RJ (2002) Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 362:755-760. (Pubitemid 34242329)
24. Silva MF, Ijlst L, Allers P, Jakobs C, Duran M, de Almeida IT, and Wanders RJ (2004) Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metab Dispos 32:1304-1310. (Pubitemid 39410917)
25. Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, and Tavares de Almeida I (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31:205-216.
26. Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40:789-801.
27. Tiffany KA, Roberts DL, Wang M, Paschke R, Mohsen AW, Vockley J, and Kim JJ (1997) Structure of human isovaleryl-CoA dehydrogenase at 2.6 A resolution: structural basis for substrate specificity. Biochemistry 36:8455-8464. (Pubitemid 27305127)
28. Verrotti A, D'Egidio C, Mohn A, Coppola G, and Chiarelli F (2010) Weight gain following treatment with valproic acid: pathogenic mechanisms and clinical implications. Obes Rev doi:10.1111/j.1467-789X.2010.00800.x.
29. Vockley J and Ensenauer R (2006) Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet 142C:95-103.
30. Willard J, Vicanek C, Battaile KP, Van Veldhoven PP, Fauq AH, Rozen R, and Vockley J (1996) Cloning of a cDNA for short/branched chain acyl-Coenzyme A dehydrogenase from rat and characterization of its tissue expression and substrate specificity. Arch Biochem Biophys 331:127-133. (Pubitemid 26230627)